Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. ESMO
  2. Guidelines
  3. ESMO-MCBS
  4. ESMO-MCBS for Solid Tumours

ESMO-MCBS Scorecards

ESMO MCBS 1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 20
4 122
3 146
2 49
1 23
NEB 6
Curative setting
A 47
C 2
NEB 3
ESMO-MCBS Scores by tumour type
Non-curative setting
Brain Tumours 2
Breast Cancer 36
Central Nervous System Malignancies 0
Endocrine Tumours 20
Gastrointestinal Cancers 66
Genitourinary Cancers 70
Gynaecological Malignancies 38
Head and neck cancer 12
Non-cancerous soft-tissue tumour 1
Refractory NTRK fusion-positive cancers 2
Sarcoma 10
Skin Cancers 29
TMB-H solid tumours 1
Thoracic Malignancies 76
Tumor agnostic 2
dMMR/MSI-H solid tumour 1
Curative setting
Brain Tumours 1
Breast Cancer 8
Central Nervous System Malignancies 1
Endocrine Tumours 0
Gastrointestinal Cancers 16
Genitourinary Cancers 3
Gynaecological Malignancies 0
Head and neck cancer 1
Non-cancerous soft-tissue tumour 0
Refractory NTRK fusion-positive cancers 0
Sarcoma 2
Skin Cancers 14
TMB-H solid tumours 0
Thoracic Malignancies 6
Tumor agnostic 0
dMMR/MSI-H solid tumour 0

The ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

reset selection
Evaluation form 1  For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR.
To evaluate ESMO-MCBS score adjustments based on quality of life .

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Therapeutic Indication Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Pralsetinib - Single arm Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant MTC who require systemic therapy ARROW
    Endocrine Tumours
    		 Thyroid Cancer - medullary RET-mutant ARROW

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Pralsetinib - Single arm Adult and paediatric patients 12 years of age and older with advanced or metastatic RETfusion-positive thyroid cancer who require systemic therapy and who are RAI-refractory ARROW
    Endocrine Tumours
    		 Thyroid cancer - differentiated RET fusion-positive ARROW

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Atezolizumab - Best supportive care Adjuvant treatment following resection and platinum-based ChT for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥1% of tumor cells IMpower010
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer PD-L1 ≥1% IMpower010

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    FINAL SCORE

    • F1

      A
    Pembrolizumab ChT with our without bevacizumab Placebo + ChT with our without bevacizumab Persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS ≥1 KEYNOTE-826
    Gynaecological Malignancies
    		 Cervical Cancer PD-L1 (CPS ≥1) KEYNOTE-826

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Pembrolizumab Cisplatin and 5-FU Placebo + cisplatin and 5-FU First-line treatment locally advanced or metastatic oesophageal or gastroesophageal junction carcinoma that is not amenable to surgical resection or definitive CRT in combination with platinum- and fluoropyrimidine-based ChT KEYNOTE-590
    Gastrointestinal Cancers
    		 Oesophageal or gastroesophageal carcinoma HER2- GEJ (all randomized) KEYNOTE-590

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      3
    Pembrolizumab Platinum and fluoropyrimidine-based chemotherapy Placebo + cisplatin and 5-FU Pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus in adults whose tumours express PD-L1 with a CPS ≥ 10 KEYNOTE-590
    Gastrointestinal Cancers
    		 Oesophageal Cancer PD-L1 CPS ≥10 KEYNOTE-590

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Pembrolizumab Cisplatin and 5-FU ChT Placebo + cisplatin and 5-FU ChT First-line treatment KEYNOTE-590
    Gastrointestinal Cancers
    		 Oesophageal or gastroesophageal carcinoma HER2- GEJ (squamous cell) KEYNOTE-590

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      3
    Pembrolizumab Cisplatin and 5-FU ChT Placebo + cisplatin and 5-FU ChT First-line treatment KEYNOTE-590
    Gastrointestinal Cancers
    		 Oesophageal or gastroesophageal carcinoma HER2- GEJ PD-L1 (squamous cell) CPS ≥10 KEYNOTE-590

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Nab-sirolimus - Single arm (Phase II) Efficacy in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa) AMPECT
    Sarcoma
    		 Perivascular epithelioid - AMPECT

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Pembrolizumab - Placebo Adjuvant treatment of adults with RCC at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions KEYNOTE-564
    Genitourinary Cancers
    		 Renal cell cancer - KEYNOTE-564

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    FINAL SCORE

    • F1

      A
    Belzutifan - Single arm (Phase II) For adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery MK-6482
    Genitourinary Cancers
    		 von Hippel-Lindau disease-associated Renal Cell Carcinoma - MK-6482

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    FOLFOX (folinic acid, fluorouracil, oxaliplatin) - Symptomatic care Second-line treatment of advanced biliary tract cancer ABC-06
    Gastrointestinal Cancers
    		 Biliary tract cancer - ABC-06

    1

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      1
    Tebentafusp - Investigator Choice (either dacarbazine, ipilimumab or pembrolizumab) Treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma IMCgp100-202
    Skin Cancers
    		 Uveal melanoma HLA-A*0201positive IMCgp100-202

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Amivantamab - Single arm Advanced NSCLC with activating EGFR exon 20 insertion mutations, after failure of platinum-based therapy CHRYSALIS
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR+ exon 20 insertion mutations CHRYSALIS

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Pembrolizumab Trastuzumab, fluoropyrimidine and platinum-containing ChT Placebo + trastuzumab, fluoropyrimidine and platinum-containing ChT First-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥1. KEYNOTE-811
    Gastrointestinal Cancers
    		 Gastric or gastroesophageal junction adenocarcinoma HER-2 positive KEYNOTE-811

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      2
    Pembrolizumab - Single arm cohort study Patients with unresectable of metastatic TMB-H solid tumours that have progressed following prior treatment and have no alternative treatment options KEYNOTE-158
    TMB-H solid tumours
    		 - TMB-H KEYNOTE-158

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Pembrolizumab - Single arm cohort study (Phase II) Patients with advanced or recurrent dMMR/MSI-H endometrial carcinoma who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation KEYNOTE-158
    Gynaecological Malignancies
    		 Endometrial Cancer dMMR/MSI-H KEYNOTE-158

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Relugolix - Leuprolide Adult patients with advanced hormone-sensitive prostate cancer HERO
    Genitourinary Cancers
    		 Prostate cancer - HERO

    4

    PRELIMINARY SCORE

    • NI

    ADJUSTMENTS

    FINAL SCORE

    • F2c
      4
    Nivo/Ipi (nivolumab and ipilimumab) - ChT First-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥1% CheckMate 648
    Gastrointestinal Cancers
    		 Oesophageal Cancer PD-L1 expression ≥1% CheckMate 648

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Nivolumab - Placebo Monotherapy for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (MIUC) with tumour cell PD-L1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of MIUC. CheckMate 274
    Genitourinary Cancers
    		 Urothelial Carcinoma PD-L1 expression ≥1% CheckMate 274

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    FINAL SCORE

    • F1

      A
    Nivolumab - Placebo Adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence after undergoing radical resection CheckMate 274
    Genitourinary Cancers
    		 Urothelial Carcinoma - CheckMate 274

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    FINAL SCORE

    • F1

      A
    Nivolumab Fluoropyrimidine and platinum-based combination ChT ChT First-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥1% CheckMate 648
    Gastrointestinal Cancers
    		 Oesophageal Cancer PD-L1 expression ≥1% CheckMate 648

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Pembrolizumab - Single arm Adult and pediatric patients with recurrent, locally advanced or metastatic Merkel cell carcinoma KEYNOTE-017
    Skin Cancers
    		 Merkel cell carcinoma - KEYNOTE-017

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Pembrolizumab - Ipilimumab Treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma KEYNOTE-006
    Skin Cancers
    		 Cutaneous Melanoma - KEYNOTE-006

    A

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a/F1
      4

      A
    Sorafenib - Placebo Treatment of HCC SHARP
    Gastrointestinal Cancers
    		 Hepatobiliary Cancers - Hepatocellular Carcinoma - SHARP

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      3
    177Lu-PSMA-617 Best standard of care (restricted) Best standard of care (restricted) In combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane based chemotherapy. VISION
    Genitourinary Cancers
    		 Prostate cancer PSMA-positive mCRPC VISION

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Relatlimab Nivolumab Nivolumab Treatment of adult and paediatric patients 12 years of age or older with unresectable or metastatic melanoma RELATIVITY-047
    Skin Cancers
    		 Cutaneous Melanoma - RELATIVITY-047

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      3
    Olaparib - Placebo Adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant ChT OlympiA
    Breast Cancer
    		 Early Breast Cancer gBRCAm HER2-negative OlympiA

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    FINAL SCORE

    • F1

      A
    Pembrolizumab - Single arm Treatment of adults with MSI-H or dMMR unresectable or mCRC after previous fluoropyrimidine-based combination therapy KEYNOTE-164
    Gastrointestinal Cancers
    		 Colorectal Cancer dMMR or MSI-H KEYNOTE-164

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Pembrolizumab - Single arm cohort study Treatment of MSI-H or dMMR tumours in adults with unresectable or metastatic gastric cancer, who have disease progression on or following at least one prior therapy KEYNOTE-158
    Gastrointestinal Cancers
    		 Gastric Cancer dMMR or MSI-H KEYNOTE-158

    2

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      2

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings

    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.